AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT OF ORAMED PHARMACEUTICALS INC.Common Stock Purchase Warrant • December 21st, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
THIS AMENDMENT AGREEMENT (this "Amendment"), made and entered into as of the 28th day of August, 2012, by and between Oramed Pharmaceuticals Inc. (the "Company") and Regals Fund LP (the "Holder").
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • December 21st, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This Agreement is entered into as of September 11, 2011 by and between HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED, a company duly incorporated under the laws of Israel, of P.O. Box 12000, Jerusalem 91120, (hereinafter: “Hadasit” or the “Institution”) and Dr. Daniel Schurr and Dr. Miriam Kidron (the ”Investigator”) on one hand and Oramed Ltd., a corporation organized under the laws of the state of Delaware, with its registered office located at 2/5 Hi-Tech Park Givat-Ram P.O. Box 39098, Jerusalem 91390, (hereinafter: “Sponsor”), on the other hand.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 21st, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this "Agreement") is dated as of November ___, 2012, among Oramed Pharmaceuticals Inc., a Delaware corporation (the "Company"), and the investors identified on the signature page hereto (each, an "Investor" and collectively the “Investors”).
Amendment to Consultant Service Agreement Dated April 21, 2009Consultant Service Agreement • December 21st, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
According to the original agreement dated April 21, 2009, the last milestone payment of 71,000 US$ was due on IND submission. Because of delays in the product development resulted in delay in IND submission, the following changes to the original agreement are introduced as agreed by the parties:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 21st, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this "Agreement") is dated as of October 30, 2012, among Oramed Pharmaceuticals Inc., a Delaware corporation (the "Company"), and D.N.A Biomedical Solutions Ltd., an Israeli company (referred to herein as "D.N.A" or an "Investor").
